fbpx
Wikipedia

Mark Walport

February 09, 2023

Sir Mark Jeremy Walport FRS FRCP FRCPath FMedSci FRSE (born 25 January 1953[1]) is an English medical scientist and was the Government Chief Scientific Adviser in the United Kingdom from 2013 to 2017[3][6][7][8][9][10][11][12] and Chief Executive of UK Research and Innovation (UKRI) from 2017[13] to 2020.[14]

Sir

Mark Walport

FRS FRCP FRCPath FMedSci FRSE
Mark Walport
Born
Mark Jeremy Walport

(1953-01-25) 25 January 1953 (age 70)[1]
London, England
EducationSt Paul's School, London
Alma materUniversity of Cambridge (PhD)[1]
Known for
Spouse
Julia Elizabeth Neild
​
​
(m. 1986)​
[1]
Childrenone son, three daughters[1]
Awards
Scientific career
FieldsImmunology
Rheumatology
Institutions
ThesisThe biology of complement receptors (1986)
Doctoral advisorPeter Lachmann[5]
Websitegov.uk/government/people/mark-walport

Education

Walport is the son of a general practitioner and was born in London. He was educated at St Paul's School, London,[1] studied medicine at Clare College, Cambridge, and completed his clinical training at Hammersmith, Guy's and Brompton Hospitals in London.[15][16] He was awarded a PhD for research into complement receptors under the supervision of Peter Lachmann in 1986 at the University of Cambridge.[17]

Career and research

Previously Walport was Director of the Wellcome Trust from 2003 to 2013.[2] Before this, he was Professor of Medicine (from 1991) and Head of the Division of Medicine (from 1997) at Imperial College London,[15] where he led a research team that focused on the immunology and genetics of rheumatic diseases.[18][19][20][21][22][23][24][25]

Walport was the eleventh Government Chief Scientific Adviser from 2013 to 2017, succeeding Sir John Beddington.

It was announced in February 2017 that Mark Walport is now Chief Executive of UK Research and Innovation (UKRI).[13]

Honours and awards

Walport was knighted in the 2009 New Year Honours list for services to medical research. He was elected an Honorary Fellow of the Royal Society of Edinburgh (FRSE) in 2017[26] and a Fellow of the Royal Society (FRS) in 2011.[4][15] His nomination for the Royal Society reads:

Mark Walport has an overwhelming case for election both for his earlier scientific work on the immunology of systemic LE and the role of complement and of defective apoptosis in its pathogenesis; and, as a general candidate, for his achievements as head of medicine at the Hammersmith Campus of Imperial College and since 2003 as Director of the Wellcome Trust. In the latter role he has provided national and international leadership at the highest level on biomedical research and policy issues and is widely recognised as a world leader in the promotion of biomedical science.[4]

References

  1. ^ a b c d e f Anon (2015). "Walport, Sir Mark (Jeremy)". Who's Who. ukwhoswho.com (online Oxford University Press ed.). A & C Black, an imprint of Bloomsbury Publishing plc. doi:10.1093/ww/9780199540884.013.U38753. (Subscription or UK public library membership required.) (subscription required)
  2. ^ a b Vogel, Gretchen (2003). "United Kingdom: Mark Walport to Take Reins at Wellcome Trust". Science. 299 (5608): 803a–. doi:10.1126/science.299.5608.803a. PMID 12574591. S2CID 70581694.
  3. ^ a b Callaway, Ewen (2012). "Britain names next chief science adviser: Immunologist Mark Walport, head of one of the world's largest biomedical charities, will take on role in 2013". Nature. 487 (7405): 20. doi:10.1038/487020a. PMID 22763530.
  4. ^ a b c Anon (2011). "Sir Mark Walport". Royal Society. Retrieved 5 July 2012. One or more of the preceding sentences incorporates text from the royalsociety.org website where:

    “All text published under the heading 'Biography' on Fellow profile pages is available under Creative Commons Attribution 4.0 International License.” -- at the Wayback Machine (archived 2016-11-11)
  5. ^ Reed, Tanya (11 July 2003). "Wellcome to a new beginning". Reporter: The newspaper of Imperial College London. No. 131.
  6. ^ Mayor, S. (2012). "Mark Walport will be next UK government chief scientific adviser, cabinet office announces". BMJ. 345: e4621. doi:10.1136/bmj.e4621. PMID 22767620. S2CID 11529948.
  7. ^ Kain, K. H. (2010). "Funding scientific discovery: An interview with Sir Mark Walport". Disease Models & Mechanisms. 3 (5–6): 265–267. doi:10.1242/dmm.005710. PMID 20427555.
  8. ^ Anon (2012). "Good advice: The UK government's latest appointment offers hope for British science". Nature. 487 (7405): 5–6. doi:10.1038/487005b. PMID 22763508.
  9. ^ Gibney, Elizabeth (29 June 2012). "New chief scientific adviser announced". Times Higher Education.
  10. ^ Mark Walport's publications indexed by the Scopus bibliographic database. (subscription required)
  11. ^ Sir Mark Walport in conversation with David Cleevely, Centre for Science and Policy (CSaP) University of Cambridge on YouTube
  12. ^ Boulton, G.; Rawlins, M.; Vallance, P.; Walport, M. (2011). "Science as a public enterprise: The case for open data". The Lancet. 377 (9778): 1633–1635. doi:10.1016/S0140-6736(11)60647-8. PMID 21571134. S2CID 3048048.
  13. ^ a b "Sir Mark Walport will lead UK Research and Innovation". www.gov.uk (Press release). 2 February 2017. Retrieved 4 July 2017.
  14. ^ "Dominic Cummings' science obsession: based on fact or fiction?". Times Higher Education (THE). 16 October 2019. Retrieved 25 November 2019.
  15. ^ a b c "Dr Sir Mark Walport". Debrett's. Retrieved 14 February 2012.
  16. ^ Morris, K. (2003). "Mark Walport". The Lancet. 362 (9382): 498–499. doi:10.1016/S0140-6736(03)14090-1. PMID 12927451. S2CID 10861093.
  17. ^ Walport, Mark Jeremy (1986). The biology of complement receptors (PhD thesis). University of Cambridge. OCLC 59761908. EThOS uk.bl.ethos.383309.
  18. ^ . Grand Challenges in Global Health. Archived from the original on 27 September 2013. Retrieved 14 February 2012.
  19. ^ Walport, M.; Foulkes, I.; Weissberg, P.; Morgan, D.; Nebhrajani, S. (2012). "Medical research: No catch to UK charity funding". Nature. 482 (7385): 308. Bibcode:2012Natur.482..308W. doi:10.1038/482308a. PMID 22337042.
  20. ^ Collins, P. Y.; Patel, V.; Joestl, S. S.; March, D.; Insel, T. R.; Daar, A. S.; Scientific Advisory Board the Executive Committee of the Grand Challenges on Global Mental Health; Bordin, I. A.; Anderson, E. J.; Dhansay, M.; Phillips, C.; Shurin, R. I.; Walport, W.; Ewart, Y.; Savill, S. E.; Bordin, K.; Costello, S.; Durkin, S.; Fairburn, A.; Glass, A.; Hall, A.; Huang, M. M.; Hyman, V.; Jamison, B. J.; Kaaya, S.; Kapur, P. A.; Kleinman, D. J.; Ogunniyi, W.; Otero-Ojeda, M. A.; Poo, W.; Ravindranath, A. (2011). "Grand challenges in global mental health". Nature. 475 (7354): 27–30. doi:10.1038/475027a. PMC 3173804. PMID 21734685.
  21. ^ Yamada, T.; Dautry, A.; Walport, M. (2008). "Ready for avian flu?". Nature. 454 (7201): 162. Bibcode:2008Natur.454..162Y. doi:10.1038/454162a. PMID 18615064. S2CID 205039550.
  22. ^ Pickering, M. C.; Warren, J.; Rose, K. L.; Carlucci, F.; Wang, Y.; Walport, M. J.; Cook, H. T.; Botto, M. (2006). "Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice". Proceedings of the National Academy of Sciences. 103 (25): 9649–9654. Bibcode:2006PNAS..103.9649P. doi:10.1073/pnas.0601094103. PMC 1476693. PMID 16769899.
  23. ^ Brown, J. S.; Hussell, T.; Gilliland, S. M.; Holden, D. W.; Paton, J. C.; Ehrenstein, M. R.; Walport, M. J.; Botto, M. (2002). "The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice". Proceedings of the National Academy of Sciences. 99 (26): 16969–16974. Bibcode:2002PNAS...9916969B. doi:10.1073/pnas.012669199. PMC 139253. PMID 12477926.
  24. ^ Botto, M.; Fong, K. Y.; So, A. K.; Barlow, R.; Routier, R.; Morley, B. J.; Walport, M. J. (1992). "Homozygous hereditary C3 deficiency due to a partial gene deletion". Proceedings of the National Academy of Sciences of the United States of America. 89 (11): 4957–4961. Bibcode:1992PNAS...89.4957B. doi:10.1073/pnas.89.11.4957. PMC 49207. PMID 1350678.
  25. ^ Taylor, P. R.; Carugati, A.; Fadok, V. A.; Cook, H. T.; Andrews, M.; Carroll, M. C.; Savill, J. S.; Henson, P. M.; Botto, M.; Walport, M. J. (2000). "A Hierarchical Role for Classical Pathway Complement Proteins in the Clearance of Apoptotic Cells in Vivo". Journal of Experimental Medicine. 192 (3): 359–366. doi:10.1084/jem.192.3.359. PMC 2193213. PMID 10934224.
  26. ^ "RSE Welcomes 60 New Fellows" (Press release). Royal Society of Edinburgh. 15 February 2017. Retrieved 28 March 2017.
  •   This article incorporates text available under the CC BY 4.0 license.
Government offices
Preceded by Government Chief Scientific Adviser
2013−2017 		Succeeded by
Cultural offices
Preceded by Director of Wellcome Trust
2003–2013 		Succeeded by

February 09, 2023
mark, walport, mark, jeremy, walport, frcp, frcpath, fmedsci, frse, born, january, 1953, english, medical, scientist, government, chief, scientific, adviser, united, kingdom, from, 2013, 2017, chief, executive, research, innovation, ukri, from, 2017, 2020, sir. Sir Mark Jeremy Walport FRS FRCP FRCPath FMedSci FRSE born 25 January 1953 1 is an English medical scientist and was the Government Chief Scientific Adviser in the United Kingdom from 2013 to 2017 3 6 7 8 9 10 11 12 and Chief Executive of UK Research and Innovation UKRI from 2017 13 to 2020 14 SirMark WalportFRS FRCP FRCPath FMedSci FRSEMark WalportBornMark Jeremy Walport 1953 01 25 25 January 1953 age 70 1 London EnglandEducationSt Paul s School LondonAlma materUniversity of Cambridge PhD 1 Known forDirector of Wellcome Trust 2003 2013 2 Government Chief Scientific Adviser 2013 2017 3 SpouseJulia Elizabeth Neild m 1986 wbr 1 Childrenone son three daughters 1 AwardsFellow of the Academy of Medical Sciences 1998 Knight Bachelor 2009 Fellow of the Royal Society 2011 4 Scientific careerFieldsImmunologyRheumatologyInstitutionsHammersmith Hospital Royal Brompton Hospital Guy s Hospital Imperial College London Imperial College School of Medicine Wellcome Trust University of Cambridge Government of the United KingdomThesisThe biology of complement receptors 1986 Doctoral advisorPeter Lachmann 5 Websitegov wbr uk wbr government wbr people wbr mark walportContents 1 Education 2 Career and research 2 1 Honours and awards 3 ReferencesEducation EditWalport is the son of a general practitioner and was born in London He was educated at St Paul s School London 1 studied medicine at Clare College Cambridge and completed his clinical training at Hammersmith Guy s and Brompton Hospitals in London 15 16 He was awarded a PhD for research into complement receptors under the supervision of Peter Lachmann in 1986 at the University of Cambridge 17 Career and research EditPreviously Walport was Director of the Wellcome Trust from 2003 to 2013 2 Before this he was Professor of Medicine from 1991 and Head of the Division of Medicine from 1997 at Imperial College London 15 where he led a research team that focused on the immunology and genetics of rheumatic diseases 18 19 20 21 22 23 24 25 Walport was the eleventh Government Chief Scientific Adviser from 2013 to 2017 succeeding Sir John Beddington It was announced in February 2017 that Mark Walport is now Chief Executive of UK Research and Innovation UKRI 13 Honours and awards EditWalport was knighted in the 2009 New Year Honours list for services to medical research He was elected an Honorary Fellow of the Royal Society of Edinburgh FRSE in 2017 26 and a Fellow of the Royal Society FRS in 2011 4 15 His nomination for the Royal Society reads Mark Walport has an overwhelming case for election both for his earlier scientific work on the immunology of systemic LE and the role of complement and of defective apoptosis in its pathogenesis and as a general candidate for his achievements as head of medicine at the Hammersmith Campus of Imperial College and since 2003 as Director of the Wellcome Trust In the latter role he has provided national and international leadership at the highest level on biomedical research and policy issues and is widely recognised as a world leader in the promotion of biomedical science 4 References Edit a b c d e f Anon 2015 Walport Sir Mark Jeremy Who s Who ukwhoswho com online Oxford University Press ed A amp C Black an imprint of Bloomsbury Publishing plc doi 10 1093 ww 9780199540884 013 U38753 Subscription or UK public library membership required subscription required a b Vogel Gretchen 2003 United Kingdom Mark Walport to Take Reins at Wellcome Trust Science 299 5608 803a doi 10 1126 science 299 5608 803a PMID 12574591 S2CID 70581694 a b Callaway Ewen 2012 Britain names next chief science adviser Immunologist Mark Walport head of one of the world s largest biomedical charities will take on role in 2013 Nature 487 7405 20 doi 10 1038 487020a PMID 22763530 a b c Anon 2011 Sir Mark Walport Royal Society Retrieved 5 July 2012 One or more of the preceding sentences incorporates text from the royalsociety org website where All text published under the heading Biography on Fellow profile pages is available under Creative Commons Attribution 4 0 International License Royal Society Terms conditions and policies at the Wayback Machine archived 2016 11 11 Reed Tanya 11 July 2003 Wellcome to a new beginning Reporter The newspaper of Imperial College London No 131 Mayor S 2012 Mark Walport will be next UK government chief scientific adviser cabinet office announces BMJ 345 e4621 doi 10 1136 bmj e4621 PMID 22767620 S2CID 11529948 Kain K H 2010 Funding scientific discovery An interview with Sir Mark Walport Disease Models amp Mechanisms 3 5 6 265 267 doi 10 1242 dmm 005710 PMID 20427555 Anon 2012 Good advice The UK government s latest appointment offers hope for British science Nature 487 7405 5 6 doi 10 1038 487005b PMID 22763508 Gibney Elizabeth 29 June 2012 New chief scientific adviser announced Times Higher Education Mark Walport s publications indexed by the Scopus bibliographic database subscription required Sir Mark Walport in conversation with David Cleevely Centre for Science and Policy CSaP University of Cambridge on YouTube Boulton G Rawlins M Vallance P Walport M 2011 Science as a public enterprise The case for open data The Lancet 377 9778 1633 1635 doi 10 1016 S0140 6736 11 60647 8 PMID 21571134 S2CID 3048048 a b Sir Mark Walport will lead UK Research and Innovation www gov uk Press release 2 February 2017 Retrieved 4 July 2017 Dominic Cummings science obsession based on fact or fiction Times Higher Education THE 16 October 2019 Retrieved 25 November 2019 a b c Dr Sir Mark Walport Debrett s Retrieved 14 February 2012 Morris K 2003 Mark Walport The Lancet 362 9382 498 499 doi 10 1016 S0140 6736 03 14090 1 PMID 12927451 S2CID 10861093 Walport Mark Jeremy 1986 The biology of complement receptors PhD thesis University of Cambridge OCLC 59761908 EThOS uk bl ethos 383309 Mark Walport PhD MB BChir Member Scientific Board Grand Challenges in Global Health Archived from the original on 27 September 2013 Retrieved 14 February 2012 Walport M Foulkes I Weissberg P Morgan D Nebhrajani S 2012 Medical research No catch to UK charity funding Nature 482 7385 308 Bibcode 2012Natur 482 308W doi 10 1038 482308a PMID 22337042 Collins P Y Patel V Joestl S S March D Insel T R Daar A S Scientific Advisory Board the Executive Committee of the Grand Challenges on Global Mental Health Bordin I A Anderson E J Dhansay M Phillips C Shurin R I Walport W Ewart Y Savill S E Bordin K Costello S Durkin S Fairburn A Glass A Hall A Huang M M Hyman V Jamison B J Kaaya S Kapur P A Kleinman D J Ogunniyi W Otero Ojeda M A Poo W Ravindranath A 2011 Grand challenges in global mental health Nature 475 7354 27 30 doi 10 1038 475027a PMC 3173804 PMID 21734685 Yamada T Dautry A Walport M 2008 Ready for avian flu Nature 454 7201 162 Bibcode 2008Natur 454 162Y doi 10 1038 454162a PMID 18615064 S2CID 205039550 Pickering M C Warren J Rose K L Carlucci F Wang Y Walport M J Cook H T Botto M 2006 Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H deficient mice Proceedings of the National Academy of Sciences 103 25 9649 9654 Bibcode 2006PNAS 103 9649P doi 10 1073 pnas 0601094103 PMC 1476693 PMID 16769899 Brown J S Hussell T Gilliland S M Holden D W Paton J C Ehrenstein M R Walport M J Botto M 2002 The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice Proceedings of the National Academy of Sciences 99 26 16969 16974 Bibcode 2002PNAS 9916969B doi 10 1073 pnas 012669199 PMC 139253 PMID 12477926 Botto M Fong K Y So A K Barlow R Routier R Morley B J Walport M J 1992 Homozygous hereditary C3 deficiency due to a partial gene deletion Proceedings of the National Academy of Sciences of the United States of America 89 11 4957 4961 Bibcode 1992PNAS 89 4957B doi 10 1073 pnas 89 11 4957 PMC 49207 PMID 1350678 Taylor P R Carugati A Fadok V A Cook H T Andrews M Carroll M C Savill J S Henson P M Botto M Walport M J 2000 A Hierarchical Role for Classical Pathway Complement Proteins in the Clearance of Apoptotic Cells in Vivo Journal of Experimental Medicine 192 3 359 366 doi 10 1084 jem 192 3 359 PMC 2193213 PMID 10934224 RSE Welcomes 60 New Fellows Press release Royal Society of Edinburgh 15 February 2017 Retrieved 28 March 2017 This article incorporates text available under the CC BY 4 0 license Government officesPreceded byJohn Beddington Government Chief Scientific Adviser2013 2017 Succeeded byChris WhittyActingCultural officesPreceded byMichael Dexter Director of Wellcome Trust2003 2013 Succeeded byJeremy Farrar Retrieved from https en wikipedia org w index php title Mark Walport amp oldid 1065715074, wikipedia, wiki, book, books, library,

article

, read, download, free, free download, mp3, video, mp4, 3gp, jpg, jpeg, gif, png, picture, music, song, movie, book, game, games.